1. The Portnoy Law Firm is investigating possible securities fraud at Soleno. 2. Class action may be filed on behalf of affected investors. 3. Soleno's VYKAT XR launch was disrupted, leading to high discontinuation rates. 4. Shares fell over 26% after an adverse report in August. 5. Past performance of the law firm shows significant recoveries for investors.
The initiation of fraud investigations typically instills investor fear, as seen in other stocks facing similar scrutiny. Historical examples show share price declines post-announcement of class actions.
The article highlights serious legal challenges that can significantly impact investor confidence and stock value.
The immediate effects on stock price are likely due to market reactions to ongoing investigations. Similar cases have shown a quick market response, usually through declines in share prices.
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., ("Soleno" or the "Company") (NASDAQ:SLNO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/soleno-therapeutics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.
On March 26, 2025, Soleno announced that the U.S. Food and Drug Administration had approved VYKAT XR (diazoxide choline) extended-release tablets for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. On November 4, 2025, Soleno revealed during its quarterly earnings call that the discontinuation rate of VYKAT XR related to adverse effects was approximately 8% at the end of the third quarter of fiscal 2025. Soleno's CEO, Anish Bhatnagar, further admitted during the call that Soleno "did see a disruption in our [VYKAT XR] launch trajectory in the wake of a short seller report that was released in mid-August, mostly in the form of a lower number of start forms and increase discontinuations for non-serious adverse events." After this news, the price of Soleno shares fell more than 26%.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
